Oppenheimer analyst Steve Lichtman tells investors in a research note that he is a buyer of Tandem Diabetes (TNDM) shares on recent weakness and ahead of its September 25 Investor & Analyst Day. Lichtman says Tandem will bring the next advanced insulin pumps to market beyond Medtronic (MDT) with Basal-IQ rolling out now and Control-IQ in summer 2019, which position Tandem well to be a share gainer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.